Introduction
Bone pain arising from symptomatic skeletal lesions is a common cause of morbidity in patients with metastatic cancer, and a majority of patients with diffuse disease require multiple treatment modalities for pain. The most common primary sites of solid tumors giving rise to such lesions are the breasts, prostate, lungs, and kidneys, together representing nearly 80% of all bony metastases. 1 If undiagnosed or inadequately treated, skeletal metastases often lead to profound pain, compression of the spinal cord, hypercalcemia, and pathological fracture of involved bones. Multiple reports suggest a direct correlation between the burden of bony metastases and survival. 2 Most bone metastases are localized to the red marrow, thus the proclivity for the axial skeleton. 3 Bone metastases are generally classifi ed as osteoblastic (increased formation of bony matrix), osteolytic (increased destruction), or mixed. Although some malignancies give rise principally to blastic or lytic lesions (prostate cancer and multiple myeloma, respectively), most maSeveral bone-seeking radionuclides can reduce pain caused by diffuse skeletal metastasis. Common-Yellowthroat_21572 . Photograph courtesy of Henry Domke, MD. www.henrydomke.com lignancies exhibit a mixed blastic-lytic phenotype. 4 Recently, the interactions between tumor-expressed surface proteins and the bone microenvironment have been better elucidated. Prostate cancer cells often express transforming growth factor beta (TGF-β), which aids in the adhesion to bone matrix and can affect the maturation of osteoclasts. 5, 6 Epidermal growth factor (EGF) may also enhance metastasis by facilitating the migration of cancer cells from circulation and into bone. 7 
Diagnosis of Bone Metastases
The diagnosis of bone metastases can be made using several diagnostic imaging techniques. The most utilized technique is the 99m Tc nuclear medicine bone scan; the radionuclide tracer, attached to an organophosphate (methylene diphosphonate), is specifi cally incorporated into the skeleton in areas of signifi cant osteoblast activity, preferentially binding to hydroxyapatite within the bone matrix. Although this type of bone scan is useful for osteoblastic metastases (such as from prostate, lung, or breast tumors), primarily osteolytic lesions (myeloma, thyroid, renal cell), generally exhibit poor uptake. Plain fi lms and computed tomography (CT) scans are sensitive for observing the destructive characteristics of such osteolytic metastases. 8 Other imaging modalities, such as magnetic resonance imaging (MRI) and 18 F sodium fl uoride (NaF) positron emission tomography (PET), may also have utility in select patients.
Treatment Options
Pain from bone metastases generally exhibits two distinct components. The fi rst is a chronic, baseline level of pain caused by local effects of bone remodeling and the infl ammatory reaction around the metastatic foci. The second component is often elicited by physical activity or with certain positions. It is more acute and severe and is often referred to as "breakthrough pain." 9, 10 Beyond nonsteroidal and narcotic analgesics, external-beam radiotherapy (EBRT) is the most common form of palliation for pain arising from bone metastases. The American Society for Radiation Oncology recently published comprehensive evidence-based guidelines for the use of palliative EBRT for bone metastases.
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Although traditional forms of radiotherapy are effective for palliation of symptoms associated with bone metastases, 12 many patients present concurrently with painful lesions in several distinct areas of the skeleton. Large-fi eld radiotherapy such as hemibody radiation therapy is effective, 13 but it has been largely abandoned due to concerns over the toxicity of radiating such large fi elds, 14 the technical challenges of providing hemibody radiation therapy, and the time-consuming nature of such a technique. For patients with diffuse symptomatic skeletal involvement, a systemic approach is often necessary. Intravenous bisphosphonates play an important role in the reduction of skeletal events in these patients.
Radionuclide Therapy
Over the past few decades, several radiopharmaceuticals have been developed with bone-seeking properties that provide palliation of pain to multiple areas of the skeleton simultaneously without the signifi cant soft-tissue toxicity and technical complications of large-fi eld EBRT. These agents are generally delivered intravenously and quickly localize specifi cally to sites of active bone reaction and remodeling. Excess radionuclides not deposited in these areas of remodeling are typically eliminated quickly from the body, either through the genitourinary or gastrointestinal system. Specifi c indications and contraindications to bone-seeking radionuclide therapy are summarized in Table 1 .
To date, seven bone-seeking radiopharmaceutical agents have shown evidence of safety and effi cacy in the medical literature (Table 2 ). Most are beta-emitters, releasing highly energetic electrons that deposit their energy over up to several millimeters in the surrounding tissues. The energies of emitted beta particles are generally not suffi cient to elicit a signifi cant cytotoxic response.
Radium-223 ( 223 Ra), a recently developed alphaemitter, releases a large helium nucleus, causing more biologic damage but over a much shorter path length and with the possibility of killing tumor cells and reducing tumor burden. Other beta-emitting radionuclides have been proposed for the treatment of bone metastases, with preclinical animal evidence of targeting to the stroma surrounding these lesions. Following is a review of the evidence for their use in patients with diffuse skeletal metastases. 
Approved Radionuclides
Phosphorus-32 ( 32 P): Although no longer in common use, the beta-emitter 32 P, in the form of a sodium orthophosphate, was the fi rst systemic radionuclide to be used for the treatment of bone metastases. It exhibits a physical half-life of 14.3 days, with an average beta particle energy of 695 keV, a mean path length of 3 mm, and a mean range in bone of 1.7 mm.
15 32 P is incorporated into hydroxyapatite and decays to sulfur-32 ( 32 S), the isotope likely responsible for the agent's effi cacy. Signifi cant myelosuppression 16 led to the abandonment of 32 P, as newer radionuclides were developed. Strontium-89 ( 89 Sr): Strontium is a member of family IIA of the periodic table and carries the same divalent charge as calcium. The body is unable to distinguish between the two elements, so the clinically utilized isotope 89 Sr is provided as a simple chloride salt and is directly incorporated into bone. 89 Sr is a beta-emitter, with a half-life of 50.5 days. The mean energy of the beta particles is 580 keV, with an average range in soft tissue of 2.4 mm and an effective range of 5 to 6 mm. 17 Less than 0.01% of the emissions are gamma rays, 18 so postinjection imaging is not performed. Osteoblastic bone metastases take up 89 Sr specifi cally in areas of osteoblastic bone metastases, with approximately 5-fold greater uptake compared to normal bone. 19 89 Sr not incorporated into bone is eliminated from the body through both the genitourinary (80%) and gastrointestinal (20%) systems. The standard prescribed dose for 89 Sr is 4 mCi for all patients. 89 Sr can be effective at palliating pain from bone metastases, particularly for metastatic prostate or breast cancer, with pain relief reported in 60% to 92% of patients. [20] [21] [22] [23] [24] Relief typically begins by the second or third week following the injection, with a median duration of approximately 6 months. One study showed a signifi cant improvement in quality of life in patients with prostate cancer due to a reduction in skeletal pain following administration of 89 Sr. 25 A brief but self-limited fl are of bone pain lasting 24 to 48 hours is not uncommon following treatment with 89 Sr. However, patients experiencing this complication may have a superior long-term palliative response compared with those who do not have a "pain fl are."
A dose-response relationship for relief of pain exists for 89 Sr for patients with metastatic prostate cancer. 26 However, dose escalation up to 10.8 mCi does not affect overall survival. 27 Combining 89 Sr with chemotherapy appears to improve pain response 28,29 and may affect survival in patients with metastatic prostate cancer. 30 Two randomized trials of 89 Sr vs EBRT alone showed similar responses for pain relief in patients with androgen-independent prostate cancer metastases, but there seemed to be a greater freedom from developing new painful sites with 89 Sr, and the US Food and Drug Administration (FDA) approval of 89 Sr was granted for this reason. 31, 32 However, overall survival was superior in the EBRT arm of a randomized trial by the European Organisation for Research and Treatment of Cancer (EORTC), and radiotherapy was less costly to deliver.
Samarium-153 ( 153 Sm): Samarium is a member of the lanthanide family of the periodic table, with several dozen isotopes described. The clinically utilized iso- 1 Yes β− = beta particle, CE = conversion electron, α = alpha particle tope is 153 Sm, a beta-emitter with a half-life of 1.9 days. Since 153 Sm has no inherent bone-seeking properties, the isotope is chelated to ethylene diamine tetramethylene phosphonate (EDTMP), which targets the bone matrix as a polyphosphonate. The mean energy of released beta particles is 233 keV, with an average range in soft tissue of 0.5 mm and an effective range of 2 to 3 mm. 33 153 Sm also releases gamma radiation (29%, 103 keV), which allows for direct scintigraphy of the administered radionuclide. 34 In fact, scintigraphic studies of patients with metastatic prostate cancer have shown identical patterns of skeletal uptake after administration of technetium-99m-methylene diphosphonate ( 99m Tc-MDP) and 153 Sm-EDTMP. 35 Approximately two-thirds of the injected dose is incorporated into the skeleton, and urinary excretion of unincorporated tracer is essentially complete within 6 hours. 36 The standard specifi c activity of 153 Sm prescribed for patients with bone metastases is 1 mCi/kg to a maximum of 150 mCi. Several studies have shown the radionuclide to be effective at palliating pain from bone metastases. [37] [38] [39] [40] [41] Palliation of pain occurs in approximately 60% to 80% of patients within 1 week of administration of 53 Sm, with a clear dose response in dose escalation studies. 42 A randomized trial using 0.5 mCi/kg vs 1.0 mCi/kg of 153 Sm in patients with bone metastases from a variety of primary tumors showed signifi cant pain improvement with the higher dose as well as superior survival in the patients with breast cancer treated with the higher dose. 43 Serafi ni et al 44 performed a double-blind, randomized controlled trial of 153 Sm-EDTMP (at 0.5 and 1.0 mCi/ kg) vs placebo in patients with skeletal metastases from solid primary tumors. Effi cacy was measured using a standard subjective visual analog scale (VAS), a blinded physician's global assessment of pain (PGA), and a record of daily use of opioids. Patients receiving the higher dose of 153 Sm reported signifi cant pain responses based on VAS at all time points (weeks 1-4) compared with placebo, whereas patients given the lower dose had improved VAS scores only at week 1. Two-thirds of patients treated at the higher dose with signifi cant pain relief at week 4 were judged by the PGA to be responders at week 16. Signifi cant reduction in opioid use was seen at the higher dose level only, compared with placebo.
Sartor et al 45 completed a double-blind (2:1), randomized controlled trial of 1.0 mCi/kg of 153 Sm-EDTMP vs placebo in patients with metastatic prostate cancer. Patients randomized to receive 153 Sm reported signifi cant improvement in subjective pain response compared with those receiving placebo in weeks 2 to 4 following injection. They also used signifi cantly fewer opioids than patients who were given placebo.
Repeat dosing with 153 Sm is both safe and effective. Two reports of patients with symptomatic bone metastases receiving multiple doses of 153 Sm showed no signifi cant differences in pain reduction or in myelosuppression after a second or third treatment. 186 Re has a half-life of 3.7 days. Its beta emission exhibits a mean energy of 349 keV and an average range in soft tissue of 1.1 mm (maximum range, 4.5 mm).
51 186 Re also emits a small gamma component (9%, 137 keV), allowing for postadministration imaging of biodistribution. 52 The short half-life and path length of 186 Re could potentially be useful in patients with poor bone marrow reserve.
One study of bone metastases from breast cancer showed palliation of bone pain in more than 90% of patients treated with 186 Re-HEDP. 53 Similar effi cacy has been seen with this agent in patients with metastatic prostate cancer. 54 The maximum tolerated dose of 186 Re-HEDP appears to be 65 mCi. 55 The PLACORHEN randomized controlled trial of 186 Re-HEDP vs placebo showed a signifi cantly higher rate of pain responders (65% vs 36%, respectively). 56 The number of patients in this study requesting palliative EBRT was higher in the placebo group than in the treatment group (67% vs 44%). Repeat administration of 186 Re-HEDP appears to be both safe and effective in select patients.
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188 Re is easily produced using an inexpensive generator, it has primarily been investigated in the developing world. 188 Re has a half-life of 0.7 days, a mean beta particle energy of 2120 keV, and an average range of 3 mm in soft tissue (maximum, 11 mm). 51 The higher beta energy for this isotope offers the potential for lethal insults to tumor cells in the region of decay. Relatively high doses (up to 70 mCi) have been given to patients with metastatic prostate cancer, with good effi cacy of pain relief. 58 The safety and effi cacy of repeat dosing of 188 Re-(Sn)HEDP have also been described.
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Tin-117m ( 117m Sn): Tin is a main group metal on the periodic table and has the greatest number of stable isotopes of all the elements. The metastable isotope 117m Sn, chelated to diethylenetriamine pentaacetic acid (DTPA), is under investigation as a possible therapeutic radionuclide for the treatment of bone metastases.
117m Sn has a half-life of 13.6 days and emits low-energy conversion electrons, with an effective path length measured in micrometers. 60 Tin is a natural bone-seeker, but its highest specifi city for bone occurs when the element is in its quatravalent state (4+). DTPA stabilizes tin in this preferred 4+ state, protecting it from competing redox reactions in vivo. 61 A comparison of dosimetric models of potential bone-seeking radionuclides performed by Bouchet et al 62 suggests that the low energy and short range of the emitted conversion electron may provide an optimal therapeutic window. In clinical studies, pain relief with 117m Sn in patients with metastatic prostate cancer has been promising, with a low risk of myelosuppression. 63, 64 Radium-223 ( 223 Ra): Radium is also a member of family IIA and may be best known for its discovery in 1898 by Marie and Pierre Curie. The propensity for ingested radium to be deposited directly into bone has been recognized for nearly a century, fi rst appreciated when workers using luminous radium-based paint began to exhibit cancers of bone and leukemias.
223 Ra (provided as a radium chloride salt solution) is an alpha-emitting isotope, with a half-life of 11.4 days and a mean path length of less than 0.1 mm in soft tissue. Its mean alpha particle energy is 5850 keV. This limited range and high linear energy transfer of the emitted alpha particle allow for potentially lethal insults to surrounding tumor cells, with minimal exposure to the nearby bone marrow.
Early experience with this investigational agent suggests a low incidence of clinically signifi cant myelosuppression, even with repeated dosing. 65 A phase II clinical trial of 223 Ra in patients with symptomatic, hormone-refractory prostate cancer showed an improvement in survival, PSA levels, and alkaline phosphatase levels compared with placebo, with no differences in hematologic toxicity. 66 Based on these early encouraging data, an international double-blind, placebo-controlled randomized trial (alpharadin in symptomatic prostate cancer [ALSYMP-CA]) was performed to compare 223 Ra with placebo (2:1 randomization) in patients with symptomatic, androgenindependent prostate cancer with skeletal metastases. 67 Patients had received docetaxel, were ineligible for the chemotherapy, or refused it. The study was stratifi ed based on alkaline phosphatase levels at registration, bisphosphonate use, and prior treatment with docetaxel. A total of 922 patients from 19 countries were enrolled in this trial, with the primary endpoint of overall survival.
At the time of the planned interim analysis, the improvement in overall survival exceeded the predetermined boundary, and the independent data monitoring committee stopped the trial. The data were presented in part at the 2011 European Multidisciplinary Cancer Congress meeting, and the authors reported a signifi cant reduction in the risk of death for patients randomized to the 223 Ra arm (hazard ratio [HR], 0.695; P = .00185), with a median overall survival of 14 vs 11.2 months. The overall survival benefi t was seen across all subgroups. The time to a skeletal-related event was also signifi cantly longer for patients in the 223 Ra arm (13.6 vs 8.4 months; P = .00046). The time to disease progression based on PSA and alkaline phosphatase levels was signifi cantly superior in the 223 Ra arm. The patients randomized to 223 Ra tolerated treatment well, with no grade 3 or 4 side effects that occurred more often with 223 Ra than with placebo. Based on the results of this pivotal trial, regulatory approval of this novel agent is expected in late 2012. In the interim, an expanded-access protocol is currently open for enrollment of patients with symptomatic metastatic androgen-independent prostate cancer. Additionally, a 60-patient phase I/II protocol examining the combination of 223 Ra with docetaxel chemotherapy for this patient population is currently open for accrual in the United States. A phase II study of 223 Ra in patients with metastatic breast cancer recently closed to accrual in Europe.
Potential Future Radionuclides
Lutetium-177 ( 177 Lu): A beta-emitter, 177 Lu is currently used for radioimmunotherapy and peptide receptor radionuclide therapy. Due to its 6.7-day half-life, maximum beta energy of 497 keV, and reliable gamma emission for imaging, 177 Lu has been considered for a number of therapeutic roles. Preclinical studies of 177 Lu-EDTMP have shown specifi c accumulation within the bones of rats. 68,69 177 Lu-EDTMP use has been reported in humans for imaging purposes. 70 Results of clinical trials have yet to be reported.
Thulium-170 ( 170 Tm): This beta-emitter is produced by thermal neutron bombardment of thulium oxide and has recently been proposed as a potential therapeutic radionuclide. 170 Tm has a long half-life (128 days), a high maximum beta energy (968 keV), and suffi cient gamma emission for imaging. Investigators from India prepared 170 Tm-EDTMP, which was shown to specifi cally accumulate in bone and reside for at least 60 days following administration in rats. 71 No human use has been reported to date.
Potential Uses of Radionuclides

Metastatic Breast Cancer
Most of the published evidence supporting the use of bone-seeking radionuclides in patients with skeletal metastases has focused on androgen-independent adenocarcinoma of the prostate, especially given its typical osteoblastic bone lesions, the usual absence of extraosseous metastases, and the paucity of effective cytotoxic chemotherapeutic options for these patients. However, many patients with widespread bone metastases from breast cancer harbor painful lesions exhibiting uptake on bone scans. Three major randomized controlled trials of bone-seeking radionuclides allowed for inclusion of 126 patients with breast cancer.
Baczyk et al 72 reported the results of a randomized controlled trial comparing 89 Sr and 153 Sm in patients with metastatic prostate cancer (n = 60) and breast cancer (n = 40). There was no difference in pain relief between the radionuclides, but patients with a mixed blastic/lytic pattern of metastases experienced less pain relief than did patients with purely blastic disease. All patients tolerated the radionuclide treatments well.
Resche et al 43 compared 0.5 and 1.0 mCi/kg of 153 Sm-EDTMP for patients with painful bone metastases. A total of 36 of the 114 patients had breast cancer. A clear dose response was described for pain relief, and the patients with the best pain relief and overall survival were those with breast cancer receiving the higher dose.
The only published randomized controlled trial of radionuclides for metastatic breast cancer was performed by Sciuto et al. 53 Patients were randomized to receive either 89 Sr or 186 Re-HEDP. Pain response and duration were similar between the groups. However, patients receiving 186 Re-HEDP obtained pain relief more quickly and recovered from transient myelosuppression signifi cantly faster than did patients treated with 89 Sr. Christensen and Petersen 73 recently performed a systematic review of the evidence for the use of radionuclides for patients with breast cancer and painful bone metastases. In addition to the three randomized controlled trials previously mentioned, they found 16 case series that included patients with metastatic breast cancer and used 89 Sr, 153 Sm, or 186 Re with palliative intent. They concluded that there is a signifi cant lack of high-level evidence supporting the use of bone-seeking radionuclides in this patient population and that randomized controlled trials are needed.
Prior to EBRT
Although most studies have evaluated either modality alone, investigators have examined the role of combining focal radiotherapy to large symptomatic sites with subsequent systemic radionuclides to address the more diffuse skeletal disease. Investigators from Turkey examined this therapeutic combination in 33 patients with diffuse, symptomatic bone metastases from a variety of solid tumors. In this nonrandomized study, the addition of either 153 Sm-EDTMP or 186 Re-HEDP provided additional pain relief beyond that reported after focal radiotherapy alone. 74 Two placebo-controlled randomized trials examining adjuvant 89 Sr following EBRT reported the opposite conclusions as to the additional pain relief provided by the radionuclide. 75, 76 However, the study by Smeland et al 76 closed early due to poor accrual, lacking the power to determine a signifi cant difference between the arms.
Administration and Side Effects of Radionuclides
In the United States, bone-seeking radionuclides are generally administered in the outpatient setting, as the lack of signifi cant gamma emission makes radiation precaution isolation procedures unnecessary. In other countries, regulatory authorities may require patients to remain in the hospital for hydration and observation for several hours or overnight after the administration. Following informed consent, the patient is identifi ed through two or more identifi ers. Intravenous access is obtained and fl ushed prior to the procedure. Patients often are hydrated prior to the injection, either orally or with up to 500 mL of normal saline, to allow for an effi cient elimination of radionuclide not incorporated into bone.
The authorized user administers the radionuclide injection through the intravenous access over approximately 1 minute. The line is fl ushed with 20 to 30 mL of normal saline, and the access is removed by the procedure nurse. The patient is then given discharge instructions as well as recommendations to drink and urinate frequently for the fi rst several hours. Typically, the injection is followed with weekly blood counts for up to 8 weeks to monitor the predictable transient decline and recovery of platelet and leukocyte counts.
The principal side effect of bone-seeking radiopharmaceuticals is transient myelosuppression. Thrombocytopenia is the most common form, with platelet counts generally exhibiting a nadir at 40% to 60% from baseline. In most patients, this event will lead to only grade 1 or 2 toxicity. Signifi cant problems with neutropenia and anemia are even less common. Approximately 5% to 10% of patients will experience a "fl are reaction," with a transient and self-limited increase in bone pain. This event is more common in patients with a signifi cant burden of bone metastases visualized on bone scan. Other uncommon side effects may include nausea, loose stools, asymptomatic hematuria, and heart palpitations.
Bone-Seeking Radionuclides and Bisphosphonates
Given the deposition of most agents in this class of radionuclides, many physicians may express concern over patients receiving both bone-seeking radionuclides and bisphosphonate therapy. A European group has reported the results of a prospective study of combined 153 Sm-EDTMP and zoledronic acid in 20 patients with metastatic, hormone-refractory prostate cancer. 77 They found no effect of zoledronic acid on the uptake of 153 Sm-EDTMP, considering combined treatment to be both safe and effective.
Conclusions
Bone-seeking radionuclides are safe and effective agents to relieve pain in patients with osteoblastic bone metastases from solid tumors, and a recent update of a Cochrane systematic review 78 supports the use of these agents for palliation of bone pain in this population, albeit with the risk of transient myelosuppression. Good candidates are those with multiple sites of symptomatic disease visualized on a nuclear medicine bone scan, with adequate baseline blood counts and pain not well controlled with analgesics.
153 Sm-EDTMP and 89 Sr are two FDA-approved agents in general clinical use in the United States. Both have been shown to be safe and effective with repeat dosing. In early-phase clinical trials, both were shown to offer additional promise when used together with cytotoxic chemotherapy, without adding signifi cant additional hematologic toxicity. Other agents in this class are under active clinical investigation and have shown similar effi cacy in early-phase clinical trials. The most promising investigational agent is 223 Ra, an alpha-emitting bone-seeking radionuclide, which led to superior overall survival in a recently reported placebo-controlled randomized clinical trial.
